Featured Research

from universities, journals, and other organizations

A potential novel drug-target for colorectal cancer treatment comes from the brain

Date:
April 27, 2011
Source:
Publicase Comunicação Científica
Summary:
Scientists have found that a brain-derived protein known to be involved in tumor growth, metastasis and drug resistance in a number of cancers, including some non-neurological cancers, is also found in colorectal cancer. The study provides the first evidence of BDNF presence in colon cancer and offers new insights into its potential contribution to tumor progression and resistance to some types of antitumor drugs.

Porto Alegre, Brazil- Tumor progression is usually ensured by more than one proliferative mechanism. When one of these is shut down by a specifically targeted drug, other mechanisms may emerge. While these events may lead to treatment failure, they may also become an opportunity for researchers to identify novel targets to be further explored. In a paper recently published in the journal Oncology, Roesler and colleagues describe a novel potential drug-target in colorectal cancer.

Related Articles


Colorectal cancer (CRC) is the fourth most common cancer in men and the third in women worldwide. It is a frequent cancer, with more than 1 million new cases every year and a poor survival rate. Rapid increases in CRC incidence have been observed mainly in emerging economies. These increases are attributed to changes in diet, life style, and patterns of physical activity. In Western countries, only 55% of the patients are alive 5 years after diagnosis, with most patients dying from metastatic disease.

Although a number of treatment options are available for CRC patients, including surgery, chemotherapy and biologic therapies targeting two different mechanisms -- angiogenesis (bevacizumab) and epidermal growth factor receptors (cetuximab and panitumumab) -- new treatment options are required to improve survival rates.

The search for novel targets led Dr. Rafael Roesler at the Federal University of Rio Grande do Sul (UFRGS) Brazil, Dr. Gilberto Schwartsmann, and graduate student Caroline Brunetto de Farias, among others, to investigate whether a brain-derived protein known to be involved in tumor growth, metastasis and drug resistance in a number of cancers, including some non-neurological cancers, could also be found in CRC.

The team led by Dr. Roesler found that the brain protein, known as brain-derived neurotrophic factor (BDNF), is present in greater amounts in colorectal tumors when compared to the normal tissue of the same patient. BDNF's receptor, a tropomyosin receptor kinase B (TrkB), is also found in CRC.

The study also shows that BDNF is potentially involved in CRC progression and CRC resistance to drugs targeted at another protein known as the gastrin-releasing peptide, or GRP. By blocking GRPR (which is GRP's receptor) with RC-3095, an antagonist molecule that inhibits proliferation in colorectal cancer cells, expression levels of BDNF may increase. Dr. Roesler and colleagues observed that when levels of BDNF were higher RC-3095-treated colorectal cells still proliferated, indicating that BDNF inhibits the anti-proliferative effects of RC-3095. On the other hand, blockage of BDNF receptor TrkB rescues the anti-proliferative effects of RC-3095. These findings suggest that BDNF is associated with a compensatory response mechanism aimed at maintaining higher proliferative levels characteristic of tumor progression.

The study provides the first evidence of BDNF and TrkB presence in colon cancer and "offers new insights into their potential contribution to tumor progression and resistance to some types of antitumor drugs" said Dr Roesler.

The research was funded by the National Council for Scientific and Technological Development (CNPq); the National Institute for Translational Medicine (INCT-TM); the UFRGS/HCPA university hospital research fund (FIPE/HCPA); the South American Office for Anticancer Drug Development; and the Children's Cancer Institute (ICI-RS).


Story Source:

The above story is based on materials provided by Publicase Comunicação Científica. Note: Materials may be edited for content and length.


Journal Reference:

  1. Caroline Brunetto de Farias, Denis Broock Rosemberg, Tiago Elias Heinen, Patricia Koehler-Santos, Ana Lucia Abujamra, Flávio Kapczinski, Algemir Lunardi Brunetto, Patricia Ashton-Prolla, Luise Meurer, Maurício Reis Bogo, Daniel C. Damin, Gilberto Schwartsmann, Rafael Roesler. BDNF/TrkB Content and Interaction with Gastrin-Releasing Peptide Receptor Blockade in Colorectal Cancer. Oncology, 2010; 79 (5-6): 430 DOI: 10.1159/000326564

Cite This Page:

Publicase Comunicação Científica. "A potential novel drug-target for colorectal cancer treatment comes from the brain." ScienceDaily. ScienceDaily, 27 April 2011. <www.sciencedaily.com/releases/2011/04/110426102422.htm>.
Publicase Comunicação Científica. (2011, April 27). A potential novel drug-target for colorectal cancer treatment comes from the brain. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2011/04/110426102422.htm
Publicase Comunicação Científica. "A potential novel drug-target for colorectal cancer treatment comes from the brain." ScienceDaily. www.sciencedaily.com/releases/2011/04/110426102422.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) — An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins